{"nctId":"NCT00048932","briefTitle":"A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis","startDateStruct":{"date":"2002-12"},"conditions":["Rheumatoid Arthritis"],"count":1795,"armGroups":[{"label":"Double-blind abatacept","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Double-blind Abatacept"]},{"label":"Double-blind Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Double-blind Placebo"]},{"label":"Open-label Abatacept","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Open-label Abatacept"]}],"interventions":[{"name":"Double-blind Abatacept","otherNames":["Orencia","BMS-188667"]},{"name":"Double-blind Placebo","otherNames":[]},{"name":"Open-label Abatacept","otherNames":["Orencia","BMS-188667"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Meet criteria of American Rheumatism Association for the diagnosis of rheumatoid arthritis and the American College of Rheumatology functional classes I, II III or IV\n* Participants must be taking 1 or more DMARDs and/or biologic approved for rheumatoid arthritis (RA) for at least 3 months and be on a stable dose for 28 days prior to Day 1.\n\nExclusion:\n\n* Other auto-immune disease as a main diagnosis (e.g. Systemic Lupus Erythematosus \\[SLE\\], Scleroderma)\n* Active tuberculosis (TB) requiring treatment within last 3 years","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Double Blind Period (DB); Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Related AEs, or AEs Leading to Discontinuation","description":"AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Related SAE/AE = possibly, probably, or certainly related to study drug","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"866","spread":null},{"groupId":"OG001","value":"417","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"534","spread":null},{"groupId":"OG001","value":"239","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"PRIMARY","title":"DB; Number of Participants With AEs of Special Interest","description":"AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"233","spread":null},{"groupId":"OG001","value":"98","spread":null}]}]}]},{"type":"PRIMARY","title":"DB; Number of Participants With Hematology Laboratories Meeting Marked Abnormality Criteria","description":"Upper Normal Limit (ULN), Lower Normal Limit (LLN), Baseline (BL). Marked abnormality criteria are: Hemoglobin (HGB): \\>3 g/dL decrease from BL; Hematocrit: \\<0.75 \\* BL; Erythrocytes: \\<0.75 \\* BL; Platelets (PLT): \\<0.67 \\* LLN/\\>1.5 \\* ULN, or if BL \\< LLN then use \\<0.5 \\* BL and \\<100,000 mm\\^3; Leukocytes: \\<0.75 \\* LLN/ \\>1.25 \\* ULN, or if BL\\<LLN then use \\<0.8 \\* BL or \\>ULN, or if BL\\>ULN then use \\>1.2 \\* BL or \\<LLN; neutrophils+bands: \\<1.0 \\* 10\\^3 c/uL; eosinophils: \\>0.750 \\* 10\\^3 c/uL; basophils: \\> 400 mm\\^3; monocytes: \\>2000 mm\\^3; lymphocytes: \\<0.750 \\* 10\\^3 c/uL/ \\>7.50 \\* 10\\^3 c/uL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"DB; Number of Participants With Blood Chemistry Laboratories Meeting Marked Abnormality (MA) Criteria","description":"ULN=upper level of normal; BL=baseline.Marked abnormality criteria: High alkaline phosphatase (ALP): \\>2\\* ULN, or if BL\\>ULN then use \\>3\\* BL; high aspartate aminotransferase (AST): \\>3\\* ULN (80 U/L), or if BL\\>ULN then use \\>4\\* BL; high alanine aminotransferase (ALT): \\>3\\* ULN (34-47 U/L), or if BL\\>ULN then use \\>4\\* BL; high G-Glutamyl transferase (GGT): \\>2\\* ULN, or if BL\\>ULN then use \\>3\\* BL; high bilirubin: \\>2\\* ULN, or if BL\\>ULN then use \\>4\\* BL; high blood urea nitrogen (BUN): \\>2\\* BL; high creatinine: \\>1.5\\* BL (ULN 14.6 pg/mg. AST ULN=80 U/L; ALT ULN=34-47 U/L;creatinine ULN=14.6 pg/mg.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"DB; Number of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Responses by Enzyme-Linked Immunosorbant Assay (ELISA)","description":"Serum samples from all treated adult participants with active rheumatoid arthritis (RA) were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null}]}]}]},{"type":"PRIMARY","title":"DB; Number of Participants With Clinically Significant Physical Examination or Vital Signs Abnormalities","description":"Physical examinations were performed at the discretion of the investigator and included breast examinations for female participants. Vital sign measurements were performed for participants before and after infusion of study medication at each visit and included seated systolic blood pressure, seated diastolic blood pressure, temperature, and heart rate. Abnormalities were determined to be clinically significant by the investigator.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Open Label Period (OL); Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Related AEs, or AEs Leading to Discontinuation","description":"AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Related SAE/AE = possibly, probably, or certainly related to study drug","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"425","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"737","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":null}]}]}]},{"type":"PRIMARY","title":"OL; Number of Participants With AEs of Special Interest","description":"AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"957","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"168","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"219","spread":null}]}]}]},{"type":"PRIMARY","title":"OL; Number of Participants With Hematology Laboratories Meeting Marked Abnormality Criteria","description":"Upper Normal Limit (ULN), Lower Normal Limit (LLN), Baseline (BL). Marked abnormality criteria are: Hemoglobin (HGB): \\>3 g/dL decrease from BL; Hematocrit: \\<0.75 \\* BL; Erythrocytes: \\<0.75 \\* BL; Platelets (PLT): \\<0.67 \\* LLN/\\>1.5 \\* ULN, or if BL \\< LLN then use \\<0.5 \\* BL and \\<100,000 mm\\^3; Leukocytes: \\<0.75 \\* LLN/ \\>1.25 \\* ULN, or if BL\\<LLN then use \\<0.8 \\* BL or \\>ULN, or if BL\\>ULN then use \\>1.2 \\* BL or \\<LLN; neutrophils+bands: \\<1.0 \\* 10\\^3 c/uL; eosinophils: \\>0.750 \\* 10\\^3 c/uL; basophils: \\> 400 mm\\^3; monocytes: \\>2000 mm\\^3; lymphocytes: \\<0.750 \\* 10\\^3 c/uL/ \\>7.50 \\* 10\\^3 c/uL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"162","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"220","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"151","spread":null}]}]}]},{"type":"PRIMARY","title":"OL; Number of Participants With Liver Function Laboratories Meeting Marked Abnormality Criteria","description":"Marked abnormality criteria: Alkaline phosphatase (ALP): \\>2\\* ULN, or if BL\\>ULN then use \\>3\\* BL; aspartate aminotransferase (AST): \\>3\\* ULN, or if BL\\>ULN then use \\>4\\* BL; alanine aminotransferase (ALT): \\>3\\* ULN, or if BL\\>ULN then use \\>4\\* BL; G-Glutamyl transferase (GGT): \\>2\\* ULN, or if BL\\>ULN then use \\>3\\* BL; Bilirubin: \\>2\\* ULN, or if BL\\>ULN then use \\>4\\* BL; blood urea nitrogen (BUN): \\>2\\* BL; creatinine: \\>1.5\\* BL","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"204","spread":null}]}]}]},{"type":"PRIMARY","title":"OL; Number of Participants With Electrolyte Laboratories Meeting Marked Abnormality Criteria","description":"Marked abnormality criteria: Sodium (Na): \\<0.95\\*LLN/ \\>1.05\\*ULN, or if BL\\<LLN then use \\<0.95\\* BL or \\>ULN, or if BL\\>ULN then use\\>1.05\\* BL or \\<LLN; potassium (K): \\<0.9\\* LLN/\\>1.1\\*ULN, or if BL\\<LLN then use \\<0.9\\* BL or \\>ULN, or if BL\\>ULN then use\\>1.1\\* BL or \\<LLN; (Cl): \\<0.9\\* LLN/\\>1.1\\* ULN, or if BL\\<LLN then use \\<0.9\\* BL or \\>ULN, or if BL\\>ULN then use\\>1.1\\* BL or \\<LLN; calcium (Ca): \\<0.8\\* LLN/\\>1.2\\* ULN, or if BL\\<LLN then use \\<0.75\\* BL or \\>ULN, or if BL\\>ULN then use\\>1.25\\* BL or \\<LLN; phosphorous (P): \\<0.75\\* LLN/ \\>1.25\\* ULN, or if BL\\<LLN then use 0.67\\* BL or \\>ULN, or if BL\\>ULN then use\\>1.33\\* BL or \\<LLN","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null}]}]}]},{"type":"PRIMARY","title":"OL; Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting Marked Abnormality Criteria","description":"MA criteria: serum glucose (Glu): \\<65 mg/dL/\\>220 mg/dL;fasting serum Glu: \\<0.8\\* LLN/\\>1.5\\*ULN,or if BL\\<LLN then use 0.8\\*BL or \\>ULN,or if BL\\>ULN then use \\>2.0\\*BL or \\<LLN;total protein: \\<0.9\\*LLN/\\>1.1\\*ULN,or if BL\\<LLN then use \\<0.9\\*BL or \\>UNL,or if BL\\>UNL then use \\>1.1\\*BL or \\<LLN; albumin: \\<0.9\\*LLN,or if BL\\<LLN then use \\<0.75 BL;uric acid: \\>1.5\\*ULN,or if BL\\>ULN then use \\>2\\*BL. Urinalysis (Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells \\[RBCs\\], White Blood Cells \\[WBCs\\]):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"207","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"647","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"125","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"310","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"429","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"403","spread":null}]}]}]},{"type":"PRIMARY","title":"OL; Number of Participants With Clinically Significant Physical Examination or Vital Signs Abnormalities","description":"Physical examinations were performed at the discretion of the investigator and included breast examinations for female participants. Vital sign measurements were performed for participants before and after infusion of study medication at each visit and included seated systolic blood pressure, seated diastolic blood pressure, temperature, and heart rate. Abnormalities were determined to be clinically significant by the investigator.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"DB; Number of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Responses by ELISA","description":"Serum samples from all treated adult participants with active rheumatoid arthritis were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":425,"n":1184},"commonTop":["UPPER RESPIRATORY TRACT INFECTION","HEADACHE","NASOPHARYNGITIS","DIARRHOEA","NAUSEA"]}}}